DOSING: The recommended initial dose of calcium acetate for adult dialysis patients is 2 tablets or capsules with each meal. The dosage may be increased gradually to reduce blood phosphate levels below 6 mg/dl without causing hypercalcemia. Most patients require 3-4 tablets or capsules with each meal.
DRUG INTERACTIONS: Calcium acetate may decrease the absorption of tetracycline (Sumycin, Actisite, Achromycin V).
PREGNANCY AND BREASTFEEDING SAFETY:
Calcium acetate may be used safely in pregnant women if calcium levels are monitored and kept within normal limits.
It is not known how much additional calcium is excreted in human milk from using calcium acetate. Calcium is a normal nutritional component of human milk.
PREPARATIONS: Tablet or capsule: 667 mg; Oral solution: 667 mg/5 ml.
STORAGE: Calcium acetate should be stored at room temperature, 15 C to 30 C (59 F to 86 F).
DRUG CLASS AND MECHANISM:
- Calcium acetate helps reduce phosphate levels in people with advanced kidney disease.
- People with advanced kidney failure retain phosphate leading to too much phosphate in their bodies (hyperphosphatemia). High phosphate levels cause hyperparathyroidism, which leads to abnormal bone formation and calcium deposits in tissues.
- Calcium acetate is a phosphate binder. Calcium acetate, when taken with meals, combines with phosphate in food to form calcium phosphate, which is poorly absorbed into the body and is excreted in the feces.
- Binding phosphate in the intestines reduces absorption of phosphate into the body.
- The FDA approved calcium acetate in December 1990.
Reference: FDA Prescibing Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.